Ampliphi Biosciences Corp Share Price Nyse
Equities
US03211P3010
Biotechnology & Medical Research
Sales 2024 * | 4.64M 370M | Sales 2025 * | 2.75M 219M | Capitalization | 86.77M 6.92B |
---|---|---|---|---|---|
Net income 2024 * | -49M -3.91B | Net income 2025 * | -63M -5.03B | EV / Sales 2024 * | 18.7 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 31.6 x |
P/E ratio 2024 * |
-1.8
x | P/E ratio 2025 * |
-1.85
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 29.65% |
Managers | Title | Age | Since |
---|---|---|---|
Deborah Birx
CEO | Chief Executive Officer | 68 | 10/07/23 |
Mina Pastagia
CTO | Chief Tech/Sci/R&D Officer | - | 25/10/20 |
Bryan Kadotani
PRN | Corporate Officer/Principal | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 11/02/20 | |
Joseph Patti
BRD | Director/Board Member | 60 | 08/05/19 |
Jules Haimovitz
BRD | Director/Board Member | 73 | 31/03/21 |
1st Jan change | Capi. | |
---|---|---|
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |